Antiphospholipid syndrome (APS) is an autoimmune disorder characterized by the presence
of antiphospholipid antibodies (aPL)(lupus anticoagulant, anticardiolipin antibodies and anti …

Objective To develop recommendations for cardiovascular risk (CVR) management in gout,
vasculitis, systemic sclerosis (SSc), myositis, mixed connective tissue disease (MCTD) …

The specific value of IgA Anti-β2glycoprotein I antibodies (aB2GP1) in the diagnosis and
management of antiphospholipid syndrome (APS) is still controversial and a matter of active …

Objective The heterogeneity of systemic lupus erythematosus (SLE) constitutes clinical and
therapeutical challenges. We therefore studied whether unrecognized disease subgroups …

Objective This study aimed to use cluster analysis (CA) to identify different clinical
phenotypes among antiphospholipid antibodies (aPL)-positive patients. Methods The …

Even though diagnosis and management pathways have been substantially improved over
the last years, autoimmune rheumatic diseases (AIRDs) such as rheumatoid arthritis (RA) …

Currently, the guidelines for the prevention of atherosclerosis in patients with
antiphospholipid syndrome (APS) do not differ substantially from those in the general …

Objective To describe the baseline characteristics of patients with positivity for
antiphospholipid antibodies (aPLs) who were enrolled in an international registry, the …

Background According to criteria for the classification of Systemic Lupus Erythematosus
(SLE), thrombocytopenia is one of the disease-defining hematologic disorders. Since the …

Abstract Purpose of the Review To review the available evidence on the management of a
variety of non-criteria manifestations in antiphospholipid syndrome (APS), including valvular …